Tumor Effect Articles & Analysis
22 news found
The data were published in an article entitled, “Gaseous Nitric Oxide Tumor Ablation Induces an Anti-Tumor Abscopal Effect,” in the peer-reviewed journal Cancer Cell International (“CCI”). ...
Meanwhile, soy peptides, consisting of immunomodulatory, antioxidant, and hypocholesterolemic effects, are reported to be beneficial to diabetes, obesity, serum lipids, etc. ...
IRVINE, Calif. – OCT. 4, 2022 – AIVITA Biomedical, Inc., a biotech company specializing in innovative cell applications, today announced that the Journal of Oncology Research and Therapy has published data from its completed Phase 2 glioblastoma (GBM) study which demonstrates enhanced progression-free survival (PFS). The publication, titled “Enhanced Progression-Free Survival in ...
As part of the RubrYc transaction, the Company now wholly-owns, with no further financial commitments, its lead immune-oncology asset, IBIO-101; an IL-2 sparing anti-CD25 antibody aimed at depleting immunosuppressive regulatory T cells without interfering with T effector cell anti-tumor effects. As iBio evaluates its recently increased options for the ...
Vascular embolization, performed by interventional radiologists, is an effective therapy for addressing the symptoms of patients suffering from this condition. Hypervascular tumors occur in both benign and malignant states and are characterized by blood supply from an abnormally large number of blood vessels. Microspheres embolization reduces or eliminates the ...
The paper also found that inhibition of this function of PAD4 reduces primary tumor growth and metastasis and enhances checkpoint inhibitor treatments. ...
IRVINE, Calif. – Apr. 5, 2022 – AIVITA Biomedical, Inc., a biotech company specializing in innovative stem cell applications, today announced the appointment of distinguished neuroscientist and industry specialist H. Christian Fibiger, Ph.D. to its board of directors. Dr. Fibiger served as vice president and global head of neuroscience at Amgen, the world’s largest ...
PD-1/PD-L1 activates human T cells to play an anti-tumor effect by releasing the inhibitory effect of tumor on cellular immunity. Its effectiveness is mainly reflected in malignant solid tumors, and it has been proved effective in a variety of malignant solid ...
IRVINE, Calif. – Mar. 9, 2022 – AIVITA Biomedical, Inc., a biotech company specializing in innovative stem cell applications, today announced that chairman and CEO Dr. Hans S. Keirstead will deliver an opening keynote at the World Immunotherapy Congress, a submeeting of the Festival of Biologics taking place March 9-11 in San Diego. Dr. Keirstead is scheduled to deliver an opening ...
About Nemvaleukin Alfa ("nemvaleukin") Nemvaleukin is an investigational, novel, engineered fusion protein comprised of modified interleukin-2 (IL-2) and the high affinity IL-2 alpha receptor chain, designed to preferentially expand tumor-killing immune cells while avoiding the activation of immunosuppressive cells by selectively binding to the intermediate-affinity IL-2 receptor ...
ByAlkermes
IRVINE, Calif. – Nov. 16, 2021 – AIVITA Biomedical, Inc., a biotech company specializing in innovative stem cell applications, today announced that chairman and CEO Dr. Hans S. Keirstead will deliver a keynote at the Vaccine World Asia Congress. The Singapore-based congress is being held virtually November 17-18. Dr. Keirstead’s speaking details are as follows: Keynote: A Fully ...
Expect to close our follow-on public offering (FPO) of 3,942,856 ordinary shares represented by American Depositary Shares (ADSs) for gross proceeds of $27.6 million before deducting underwriter fees and commissions and other offering expenses Data reported in early July 2021 from EVX-01 Phase 1/2a clinical trial showed a robust anti-tumor effect in ...
IRVINE, Calif. – Nov. 8, 2021 – AIVITA Biomedical, Inc., a biotech company specializing in innovative stem cell applications, today announced that chairman and CEO Dr. Hans S. Keirstead will chair a keynote panel and speak on consecutive days at the World Immunotherapy Congress Europe. The congress is part of the Festival of Biologics taking place in Basel, Switzerland, November 9-11. ...
Conducted by a joint team of breast surgeons and radiation oncologists at Brown University and Tufts Medical Center, the analysis compared the repeatable delineation of the tumor bed after lumpectomy for radiation therapy planning and treatment as well as safety and effectiveness. ...
IRVINE, Calif. – Oct. 4, 2021 – AIVITA Biomedical, Inc., a biotech company specializing in innovative stem cell applications, today announced that chairman and CEO Dr. Hans S. Keirstead will deliver a keynote address at the Advanced Therapies Congress & Expo in London, taking place October 5-6. Dr. Keirstead will speak at the following time and location: Keynote: Cell-based ...
Even more importantly, the biomarker data indicates that ongoing vector replication in tumors effectively translates into sustained production of the transgene payload, in this case a CD40 agonistic antibody. This translational data is a first in class demonstration of a downstream effect of tumor re-engineering, using T-SIGn ...
The trial demonstrated that the therapy was safe and well-tolerated and induced T cell responses against multiple tumor targets. Robust immune responses by patients correlated to clinical benefits. ...
Follow this link to the AACR web site and this link to see our Poster: Abstract Elevated levels of adenosine found in the tumor microenvironment have been highlighted as a potential mechanism contributing to the restricted efficacy of immune checkpoint inhibitors. ...
Irinotecan is a well-established chemotherapy with documented anti-cancer effects. It is approved for treating colorectal and pancreatic cancer as well as for gastric cancer in Japan. ...
The presentation is entitled “STACT: A Novel Therapeutic Platform that Delivers Immunomodulatory Payloads to Tumor-Resident Myeloid Cells After IV Dosing and Demonstrates Potent Anti-Tumor Efficacy in Preclinical Studies”. ...